SAABR trial (atezolizumab): what clinicians have said so far
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
- NCT04262154 ↗
- Active, not recruiting
- Memorial Sloan Kettering Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on SAABR (atezolizumab plus abiraterone plus prednisone; atezolizumab plus enzalutamide in newly diagnosed hormone-sensitive metastatic prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SAABR so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- SAABR: Single Arm Phase II Study of AR Targeted Therapy + Atezolizumab + GnRH Analog and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men With Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Atezolizumab; Abiraterone; Prednisone; GnRH analog; Stereotactic Body Radiotherapy (SBRT); Enzalutamide; Follow up
- Arms
- Metastatic Prostate Cancer · Experimental
- Enrollment
- 28
- Primary outcomes
- Failure-free Rate at 2 Years
- Sponsor
- Memorial Sloan Kettering Cancer Center with Genentech, Inc., Stand Up To Cancer
- Start
- Mar 3, 2020
- Primary completion
- Jul 7, 2025
- Results posted
- Yes
- Registry record
- NCT04262154 · updated Oct 22, 2026